Amniotic Membrane Market
Executive Summary
The global market was valued at USD 5.7 billion in 2025 and is projected to reach USD 11.4 billion by 2033, at a CAGR of 9.1%.
Market Dynamics & Scope
Cryopreserved amniotic membranes accounted for around 60.0% of revenue in 2025 and are growing fastest, alongside dehydrated membranes. Hospitals represent over 39.0% of end-use demand, while ambulatory surgical centers and ophthalmology are the fastest-growing end-use and application segments.
This report covers revenue forecasts from 2021 to 2033 across product, application, end use, and region, and profiles 11 leading regenerative medicine companies.
Key Market Trends & Insights
By application: Others (dermatology, dentistry, gynecology) held over 42.0% share in 2025, while ophthalmology is projected to grow at the fastest CAGR.
By end use: Hospitals held the largest share of over 39.0% in 2025, while ambulatory surgical centers (ASCs) are projected to register the fastest CAGR.
Regional Highlights
Fastest-growing regional market: Asia Pacific (highest CAGR, 2026-2033, led by China and Japan)
Market Size & Forecasts
Estimated market size in 2026: USD 5.2 Billion
Projected market size by 2033: USD 12.4 Billion
CAGR (2026-2033): 13.1%
Analyst Perspective
End-use Insights
Product Insights
Application Insights
Regional Insights
Market Dynamics
Driver
Rising geriatric population and ophthalmic surgical volumes; proven bacteriostatic, anti-inflammatory, and anti-scarring properties in chronic wound and corneal healing; expanding stem-cell and regenerative medicine R&D.
Restraint
Stringent regulatory classification and BLA approval timelines, cold-chain storage requirements for traditional cryopreserved grafts, and reimbursement variability.
Opportunity
Shelf-stable hydrated cryopreserved grafts, injectable micronized dHACM formulations for orthopedic and surgical use, and rapid outpatient adoption in ambulatory surgical centers.
Regional & Country Trends
U.S. Market Trends
The U.S. anchors North America's 33.0% global share (and is projected to reach USD 2,208.0 million by 2030 in GVR's Horizon outlook), supported by FDA Section 361 allograft recognitions, Phase III clinical trials, and more than 12,400 ASCs.
Europe Market Trends
Europe is a major market led by the UK (projected at 12.6% CAGR to USD 378.7 million by 2030), Germany, France, Italy, and Spain across ophthalmic and chronic wound clinics.
Asia Pacific Market Trends
Asia Pacific is the fastest-growing region, led by China and Japan, where long-term clinical studies (such as Kyoto Prefectural University of Medicine's 21-year ocular study) and improving surgical infrastructure drive adoption.
Key Company Insights & Competitive Landscape
Key Companies Profiled:
Amnio Technology, LLC; Applied Biologics LLC; Human Regenerative Technologies, LLC; Integra LifeSciences; LifeNet Health; Katena Products, Inc.; MiMedx Group, Inc.; Skye Biologics Holdings, LLC; BioTissue; Organogenesis Inc.; Amniox Medical Inc.
Recent Industry Developments
August 2025: BioLab Holdings announced that the U.S. FDA's Tissue Reference Group recognized five of its amniotic membrane allografts under Section 361.
August 2024: Organogenesis completed enrollment (594 patients) in its second Phase III trial of ReNu cryopreserved amniotic suspension allograft for knee osteoarthritis; in June 2024, BioTissue launched CAM360 AmnioGraft.
Global Report Segmentation
Application: Surgical Wounds; Ophthalmology; Others
End Use: Hospitals; Ambulatory Surgical Centers; Specialty Clinics; Research Institutes and Academic Institutes
Region: North America (U.S., Canada, Mexico); Europe (UK, Germany, France, Italy, Spain, Denmark, Sweden, Norway); Asia Pacific (Japan, China, India, Australia, South Korea, Thailand); Latin America (Brazil, Argentina); Middle East & Africa (South Africa, Saudi Arabia, UAE, Kuwait)
Select License Type
Immediate PDF Delivery
24/7 Analyst Support Desk